FDA Issues Warning to Calibrate IV Hydration
The regulatory body cited the company for marketing unapproved umbilical cord and exosome products.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Do you trust medical treatments marketed online that lack formal FDA approval?
The FDA issued a warning letter to Calibrate IV Hydration after determining the firm markets unapproved biological products. The agency found these items lack required premarket review and licensure.
Why it matters
The FDA warning highlights the strict regulatory requirements for biological products and the potential risks associated with unproven medical treatments. The agency is cracking down on the sale of unlicensed substances marketed for various therapeutic conditions.
The firm must provide a written response to the FDA regarding their marketing violations within 15 working days. Failure to address these concerns may result in legal enforcement actions, such as product seizure or a federal injunction.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
Calibrate IV Hydration
This company operates as a provider of various wellness and hydration treatments marketed through its digital platform.
The details
The FDA's October 2026 review of calibrateiv.com found that the company promotes umbilical cord-derived and exosome products without an approved biologics license application. These products were marketed for uses in neurology, immunology, orthopedics, endocrinology, and skin health without meeting the regulatory standards set under the Public Health Service Act.
Timeline
In October 2026, the FDA reviewed the marketing claims on the company website.
The FDA issued the official warning letter to the company on October 13, 2026.
The company has 15 working days following the receipt of the letter to submit a written response.
Market Landscape
This enforcement action aligns with the broader application of the Federal Food, Drug, and Cosmetic Act to ensure medical integrity in the wellness market. It positions the FDA against firms that attempt to bypass established clinical review processes for biological products.
Patients should be aware that the products identified by the FDA lack federal approval for safety and efficacy. Consumers relying on such treatments for medical conditions face potential health risks and should consult licensed healthcare providers.
The takeaway
The FDA's action serves as a reminder to verify that medical products are backed by scientific review before use. Patients should prioritize treatments that have received explicit regulatory approval for their intended purposes.
What happens next
The company must submit its formal written response to the FDA within 15 working days of receiving the warning letter.
Further reading
For more information on regulatory oversight, visit the United States Healthcare section.
More information
View the FDA public safety notification for exosome products for further guidance.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Do you trust medical treatments marketed online that lack formal FDA approval?
